{"disease":{"id":"respiratory-syncytial-virus-hospitalizations","name":"respiratory syncytial virus hospitalizations"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07164430","title":"The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT07177508","title":"First Year Impact of Nirsevimab on Paediatric Respiratory Syncytial Virus Infection and Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2355,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT02273882","title":"An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants","phase":"","overall_status":"COMPLETED","enrollment_count":497,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}